Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

By G. Montalescot, S. Wiviott, E. Braunwald, S. Murphy, C. Gibson, C. Mccabe, E. Antman. The Lancet, 2009

1,090 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Immunology

View Paper: https://www.semanticscholar.org/paper/234dc89b2250d8a669c77f10ec7c424a8c1152b7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012, neutral): “In the subset of patients with STEMI undergoing primary or secondary PCI, the benefit was consistent, without significant increase in non-CABG-related bleeding risk.(111) Prasugrel is contraindicated in patients with prior stroke/transient ischaemic attack (TIA).”
[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, methodology): “[33] or ticagrelor [20] were allowed as per protocol in patients with prior treatment with lysis in P2Y12 inhibitor-naı̈ve patients or those with prior clopidogrel administration, respectively, there are insufficient safety data to recommend their concomitant use during or soon after thrombolysis.”
2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. (2011, background): “At least two new P2Y12 inhibitors are available for clinical use [23, 24].”
Guidelines on myocardial revascularization. (2010, background): “Prasugrel is superior to clopidogrel (300mg loading dose, 75mg maintenance dose) in reducing combined ischaemic endpoints and stent thrombosis in STEMI patients without increasing the risk of severe bleeding [252].”
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) (2009, methodology): “Data were consistent in both the primary and secondary PCI subgroups.(13) The writing group weighed the current data regarding the use of thienopyridine therapy in patients who remain hospitalized after STEMI and are candidates for CABG and retained the 2007 focused update recommendation of empiric ”
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, neutral): “, 2009 (25) 19249633 Aim: To asses prasugrel vs.”
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “raphy and was limited to 300 mg, may have contributed to differences in efficacy and safety between treatment groups.(262)”